ICR’s ‘resistance-busting’ drug advances into Phase I trial
EP0042 is a dual-inhibitor drug designed to block the activity of two cancer-driving proteins
Read More
Tag: neuroblastoma
New drug shows potential for treating childhood neuroblastoma
Drug is ready to progress into clinical trials after passing initial safety test
Read More
Could Prozac help fight neuroblastoma?
Previous studies have found that people on long-term treatment for psychotic illnesses have lower cancer rates.
Read More
SMC endorses EUSA Pharma’s Qarziba
A medicine used to treat a rare cancer that predominantly occurs in very young children is to be routinely funded on the NHS in Scotland.
Read More
NICE backs Qarziba for children with high-risk neuroblastoma
NHS funding for EUSA’s Pharma’s Qarziba has been approved to treat children with high-risk neuroblastoma.
Read More
Long-term benefit of Qarziba uncertain, says NICE
The National Institute for Health and Care Excellence has ruled against the provision of NHS funding for EUSA Pharma’s neuroblastoma treatment Qarziba.
Read More
EU approves first immunotherapy for neuroblastoma
EU regulators have issued a green light for the first immunotherapy for high-risk neuroblastoma, offering thousands of children affected by the rare and devastating form of cancer a new treatment option.
Read More
Six new medicines backed for EU approval
Six new medicines, including three orphan drugs for rare diseases, have been backed for European Union approval by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).
Read More
- SolasCure trial shows faster healing with Aurase Wound Gel
- Gilead data show investigational HIV combination maintains viral suppression
- Verdiva Bio completes enrolment for phase 2b study of oral GLP‑1 candidate VRB‑101
- MHRA approves imlunestrant tosylate as new breast cancer treatment
- ACD440 granted orphan drug status in the EU
